MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$38,484K
(49.34%↑ Y/Y)
(benefit) from / provision
for income taxes
-$15K
Ongoing Performance
Related To Unsatisfied...
$11,958K
Materials Supply
$1,083K
Financing Component On
Unearned Revenue
$911K
Research And Development
Services
$556K
Loss before
provision for income taxes
-$38,499K
Interest income
$1,635K
(-48.73%↓ Y/Y)
Astellas Pharma Inc
Astellas
$14,508K
(-14.05%↓ Y/Y)
Vaxcyte Inc
$15K
(-93.27%↓ Y/Y)
Loss from operations
-$29,656K
(56.72%↑ Y/Y)
Non-cash interest
expense related to the...
$9,467K
(1.32%↑ Y/Y)
Revenue
$14,523K
(-16.53%↓ Y/Y)
Interest and other income
(expense), net
-$1,011K
(22.17%↑ Y/Y)
Total operating
expenses
$44,179K
(-48.58%↓ Y/Y)
Research and development
$36,553K
General and
administrative
$7,584K
Restructuring and related
costs
$42K
Back
Back
Income Statement
source: myfinsight.com
SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC. (STRO)